Literature DB >> 18364349

Roles of Necl-5/poliovirus receptor and Rho-associated kinase (ROCK) in the regulation of transformation of integrin alpha(V)beta(3)-based focal complexes into focal adhesions.

Yuichi Nagamatsu1, Yoshiyuki Rikitake, Motonori Takahashi, Yuko Deki, Wataru Ikeda, Ken-ichi Hirata, Yoshimi Takai.   

Abstract

Focal complexes are continuously formed and transformed into focal adhesions during cell movement. We previously demonstrated that Necl-5 co-localizes with integrin alpha(V)beta(3) at focal complexes, whereas Necl-5 does not localize at focal adhesions in moving NIH3T3 cells, suggesting that Necl-5 may be dissociated from integrin alpha(V)beta(3) during the transformation of focal complexes into focal adhesions, but the underlying mechanism remains unknown. Here, we explore the roles of Necl-5 and Rho-associated kinase (ROCK) in the regulation of the transformation of focal complexes into focal adhesions. We found that inhibition of Necl-5 expression and expression of a constitutively active mutant of ROCK1 enhanced, whereas treatment with a ROCK inhibitor Y-27632 inhibited the transformation of focal complexes into focal adhesions. In HEK293 cells ectopically expressing Necl-5 and integrin alpha(V)beta(3), treatment of cells with Y-27632 increased the binding of Necl-5 to clustered integrin alpha(V)beta(3). The experiments using inhibitors of myosin ATPase and actin polymerization revealed that actomyosin-driven contractility exerts a similar function as ROCK. The phosphorylation of integrin beta(3) at Tyr(747), which is known to be critical for the formation of focal adhesions, plays a pivotal role for the interaction between Necl-5 and integrin alpha(V)beta(3). These results indicate that the transformation of focal complexes into focal adhesions is negatively and positively regulated by Necl-5 and ROCK, respectively, and that ROCK-dependent actomyosin-driven contractility is a critical determinant for the regulation of the interaction between Necl-5 and integrin alpha(V)beta(3).

Entities:  

Mesh:

Substances:

Year:  2008        PMID: 18364349     DOI: 10.1074/jbc.M801647200

Source DB:  PubMed          Journal:  J Biol Chem        ISSN: 0021-9258            Impact factor:   5.157


  5 in total

1.  Role of scaffold protein afadin dilute domain-interacting protein (ADIP) in platelet-derived growth factor-induced cell movement by activating Rac protein through Vav2 protein.

Authors:  Yuri Fukumoto; Souichi Kurita; Yoshimi Takai; Hisakazu Ogita
Journal:  J Biol Chem       Date:  2011-10-25       Impact factor: 5.157

2.  Interaction of nectin-like molecule 2 with integrin alpha6beta4 and inhibition of disassembly of integrin alpha6beta4 from hemidesmosomes.

Authors:  Kiyohito Mizutani; Satoshi Kawano; Akihiro Minami; Masazumi Waseda; Wataru Ikeda; Yoshimi Takai
Journal:  J Biol Chem       Date:  2011-08-31       Impact factor: 5.157

3.  Functional whole-genome analysis identifies Polo-like kinase 2 and poliovirus receptor as essential for neuronal differentiation upstream of the negative regulator alphaB-crystallin.

Authors:  Cristina Draghetti; Catherine Salvat; Francisca Zanoguera; Marie-Laure Curchod; Chloé Vignaud; Helene Peixoto; Alessandro Di Cara; David Fischer; Mohanraj Dhanabal; Goutopoulos Andreas; Hadi Abderrahim; Christian Rommel; Montserrat Camps
Journal:  J Biol Chem       Date:  2009-08-21       Impact factor: 5.157

4.  Regulation by afadin of cyclical activation and inactivation of Rap1, Rac1, and RhoA small G proteins at leading edges of moving NIH3T3 cells.

Authors:  Muneaki Miyata; Yoshiyuki Rikitake; Motonori Takahashi; Yuichi Nagamatsu; Yusuke Yamauchi; Hisakazu Ogita; Ken-ichi Hirata; Yoshimi Takai
Journal:  J Biol Chem       Date:  2009-07-09       Impact factor: 5.157

5.  Alternative splicing and transcriptome profiling of experimental autoimmune encephalomyelitis using genome-wide exon arrays.

Authors:  Alan Gillett; Klio Maratou; Chris Fewings; Robert A Harris; Maja Jagodic; Tim Aitman; Tomas Olsson
Journal:  PLoS One       Date:  2009-11-10       Impact factor: 3.240

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.